With the final hurdle for their $63 billion merger cleared in the EU, AbbVie and Allergan were in the home stretch to close the deal. Then the novel coronavirus took off, and now that merger could be further out of reach as regulatory bodies prepare to pump the brakes.
AbbVie and Allergan’s pending merger may face a regulatory delay after the Federal Trade Commission (FTC) and the U.S. Department of Justice’s (DOJ’s) antitrust division warned they may need additional time to review due to disruptions from COVID-19, Bloomberg reported Tuesday.
While the FTC said in a statement that its operations are running “without interruption,” the commission told Bloomberg that the two drugmakers could have issues producing documents and making employees available for review.
Full Content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.